Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections

摘要: The availability of reproducible antifungal susceptibility testing methods now permits analysis data correlating in vitro with outcome vivo order to define interpretive breakpoints. In this paper, we have examined the conceptual framework underlying interpretation antimicrobial results and then used these ideas drive packages developed by respective manufacturers that correlate fluconazole itraconazole MICs candidal infections. Tentative breakpoints for determined National Committee Clinical Laboratory Standards' M27-T broth macrodilution methodology are proposed: isolates which or = 64 microg/mL appear resistant. Isolates MIC is 16-32 considered susceptible dependent upon dose (S-DD), on basis indicating clinical response when > 100 mg per day given. These do not, however, apply Candida krusei, as it inherently resistant fluconazole. only mucosal infections follows: susceptible, 1.0 microg/mL. tentative open public commentary.